AptarGroup, Inc.

Análisis de la acción AptarGroup, Inc. (ATR)

$131.620

-1.356 (-1.03%)Al cierre

Loading chart…
High
132.440
Open
132.210
VWAP
131.63
Vol
389.24K
Mkt Cap
9.53B
Low
130.830
Amount
51.24M
EV/EBITDA, TTM
12.08

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.

www.aptar.com

AI analysis of AptarGroup, Inc. (ATR)

buy

AptarGroup Inc is a good buy right now due to its recent strong earnings report, which showed a non-GAAP EPS of $1.42, beating expectations by $0.07, and a revenue growth of 6.6% year-over-year to $1.03 billion. Additionally, the forward P/E ratio of 17.54 suggests that the stock is relatively undervalued compared to its growth potential. However, the RSI of 41.17 indicates that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent 5-day price change of -1.34%, indicating short-term volatility.

Analyst Ratings (9)

+10.42% upside
Hold
2 Buy
6 Hold
1 Sell
Current: 131.62
Mínimo
133.00
Promedio
145.33
Máximo
156.00

BofA

2026-07-31

Precio objetivo

$172

Buy

Raymond James

2026-07-15

Precio objetivo

$160

Outperform

BofA

2026-07-14

Precio objetivo

$173

Buy

Wells Fargo

2026-05-04

Precio objetivo

$145

Overweight

BofA

2026-04-06

Precio objetivo

$145

Neutral

Métricas de valoración

The current forward P/E ratio for AptarGroup, Inc. (ATR) is 17.24, compared to its 5-year average forward P/E of 25.67.

Forward P/E

Strongly Undervalued
5Y Average P/E
25.67
Current P/E
17.24
Sobrevalorada
29.24
Infravalorada
22.09

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
12.85
Current EV/EBITDA
12.08
Sobrevalorada
13.88
Infravalorada
11.81

Forward P/S

Fair
5Y Average P/S
2.33
Current P/S
2.04
Sobrevalorada
2.64
Infravalorada
2.03

Alphio AI Price Scenarios for ATR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ATR

$180.85

Precio del escenario

B

Base

Base · 50%ATR

$171.26

Precio del escenario

B

Bear

Bear · 25%ATR

$163.57

Precio del escenario

Whales holding ATR

C

Crawford Investment Counsel, Inc.

+ HoldingATR

+9.72%

3M Return

F

Fiduciary Management, Inc.

+ HoldingATR

+4.93%

3M Return

E

Edgestream Partners, L.P.

+ HoldingATR

+3.60%

3M Return

S

Schwartz Investment Counsel, Inc.

+ HoldingATR

+3.29%

3M Return

H

Hemenway & Barnes LLP

+ HoldingATR

+2.87%

3M Return

W

Williams Jones Wealth Management, LLC

+ HoldingATR

+2.19%

3M Return

Cronología de eventos

2026-07-30 (ET)

17:30:00

Aptar Reports Q2 Revenue of $1.03B, Beating Expectations

17:30:00

Aptar Optimistic About Q3 Outlook

2026-04-30 (ET)

17:10:00

Aptar CEO Predicts Growth Across Segments in Q2

17:10:00

Aptar Q1 Revenue $982.9M Beats Expectations

2026-03-19 (ET)

17:10:00

AptarGroup Collaborates with ENA Respiratory on INNA 051 Clinical Study

Noticias

ATR FAQ — answered by Alphio AI

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).

AptarGroup Inc is a good buy right now due to its recent strong earnings report, which showed a non-GAAP EPS of $1.42, beating expectations by $0.07, and a revenue growth of 6.6% year-over-year to $1.03 billion. Additionally, the forward P/E ratio of 17.54 suggests that the stock is relatively undervalued compared to its growth potential. However, the RSI of 41.17 indicates that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent 5-day price change of -1.34%, indicating short-term volatility.

9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis